Stock BJP BEIT JALA PHARMACEUTICAL COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Beit Jala Pharmaceutical Company

Equities

BJP

PS2017111704

Pharmaceuticals

End-of-day quote Palestine Exchange
Other stock markets
 06:00:00 2023-10-22 pm EDT 		5-day change 1st Jan Change
2.8 JOD +1.45% Intraday chart for Beit Jala Pharmaceutical Company -.--% -.--%
Mar. 14 Beit Jala Pharmaceutical Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Beit Jala Pharmaceutical Company Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 16.8 16.87 17.85 18.9 19.95 19.6
Enterprise Value (EV) 1 16.89 17.79 19.91 21.37 20.69 19.84
P/E ratio 21.7 x 12.4 x 23.9 x 21.7 x 10.1 x 10.7 x
Yield - 6.22% 3.92% 3.7% 3.51% -
Capitalization / Revenue 2.39 x 1.91 x 2.05 x 1.94 x 1.85 x 2.04 x
EV / Revenue 2.4 x 2.02 x 2.29 x 2.19 x 1.92 x 2.06 x
EV / EBITDA 12.9 x 8.14 x 10.1 x 10.1 x 6.26 x 6.09 x
EV / FCF -8.06 x -34.5 x -48.9 x -46.3 x 9.99 x -501 x
FCF Yield -12.4% -2.9% -2.05% -2.16% 10% -0.2%
Price to Book 1.44 x 1.39 x 1.49 x 1.52 x 1.51 x 1.34 x
Nbr of stocks (in thousands) 7,000 7,000 7,000 7,000 7,000 7,000
Reference price 2 2.400 2.410 2.550 2.700 2.850 2.800
Announcement Date 3/30/19 4/12/20 4/24/21 3/31/22 4/1/23 4/17/24
1JOD in Million2JOD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 7.037 8.814 8.69 9.755 10.77 9.612
EBITDA 1 1.312 2.186 1.979 2.116 3.305 3.258
EBIT 1 0.7113 1.477 1.053 1.107 2.355 2.158
Operating Margin 10.11% 16.76% 12.12% 11.35% 21.87% 22.45%
Earnings before Tax (EBT) 1 0.8223 1.486 0.882 1.052 2.365 1.961
Net income 1 0.7728 1.363 0.7453 0.8711 1.981 1.837
Net margin 10.98% 15.47% 8.58% 8.93% 18.4% 19.11%
EPS 2 0.1104 0.1948 0.1065 0.1244 0.2830 0.2625
Free Cash Flow 1 -2.094 -0.5162 -0.4076 -0.4612 2.072 -0.0396
FCF margin -29.76% -5.86% -4.69% -4.73% 19.25% -0.41%
FCF Conversion (EBITDA) - - - - 62.7% -
FCF Conversion (Net income) - - - - 104.6% -
Dividend per Share - 0.1500 0.1000 0.1000 0.1000 -
Announcement Date 3/30/19 4/12/20 4/24/21 3/31/22 4/1/23 4/17/24
1JOD in Million2JOD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.09 0.92 2.06 2.47 0.74 0.24
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 0.065 x 0.4193 x 1.042 x 1.169 x 0.2251 x 0.0726 x
Free Cash Flow 1 -2.09 -0.52 -0.41 -0.46 2.07 -0.04
ROE (net income / shareholders' equity) 6.43% 11.5% 6.18% 7.13% 15.5% 13.2%
ROA (Net income/ Total Assets) 2.74% 5.76% 3.92% 3.77% 7.6% 7.22%
Assets 1 28.16 23.67 19.02 23.09 26.08 25.43
Book Value Per Share 2 1.660 1.730 1.710 1.780 1.890 2.080
Cash Flow per Share 2 0.2400 0.1400 0.0200 0.1200 0.1600 0.1000
Capex 1 2.99 1.24 2.02 0.82 0.4 1.27
Capex / Sales 42.46% 14.03% 23.23% 8.41% 3.74% 13.17%
Announcement Date 3/30/19 4/12/20 4/24/21 3/31/22 4/1/23 4/17/24
1JOD in Million2JOD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
BEIT JALA PHARMACEUTICAL COMPANY Stock Beit Jala Pharmaceutical Company
-.--% 27.65M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BJP Stock
  4. Financials Beit Jala Pharmaceutical Company